Finance

Lists
ONCY:NASDAQ
Oncolytics Biotech Inc
$ 0.67
+1.19%
(+0.0079) 1D
9-р сарын 29, 11:04:02 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONCY...
Open
$ 0.67
High
$ 0.68
Low
$ 0.66
Mkt. cap
85.94 сая
Avg. vol.
955.48 мян
Volume
160.69 мян
52-wk high
$ 1.47
52-wk low
$ 0.64
Beta
1.15
Shares outstanding
127.51 сая
No. of employees
29
Open
$ 0.67
High
$ 0.68
Low
$ 0.66
Mkt. cap
85.94 сая
Avg. vol.
955.48 мян
Volume
160.69 мян
52-wk high
$ 1.47
52-wk low
$ 0.64
Beta
1.15
Shares outstanding
127.51 сая
No. of employees
29
News stories
From web sources and news partners
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc
CEO-
Employees29
Founded1998
HeadquartersКалгари, Альберта, Канад
Sector-
Analyst ratings
Based on 2 analysts giving stock ratings to ONCY in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ONCY in the last 3 months.
Highest
Current $ 0.67
$ 5.00 (+645.27%)
Average
$ 5.00 (+645.27%)
Lowest
$ 5.00 (+645.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Boris Peaker
JonesTrading
Hold
Maintained
-
-
09/27/2026
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
$ 5.00
+645.3%
09/21/2026
Chad Messer
Lake Street
Buy
Maintained
$ 5.00
+645.3%
06/01/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
$ 3.00
+347.2%
05/21/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
04/06/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
2024 оны 12-р сар
2025 оны 3-р сар
2025 оны 6-р сар
2025 оны 9-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
7.52 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
6.32 сая
Operating expense
-
-
-
13.84 сая
Total operating expenses
-
-
-
13.84 сая
Operating income
-
-
-
-13.84 сая
Other non operating income
-
-
-
-1.05 сая
EBT including unusual items
-
-
-
-14.65 сая
EBT excluding unusual items
-
-
-
-14.65 сая
Income tax expense
-
-
-
-252.00 мян
Effective tax rate
-
-
-
1.72%
Other operating expenses
-
-
-
-
Net income
-
-
-
-14.40 сая
Net profit margin
-
-
-
-
Earnings per share
-0.10
-0.08
-0.07
-0.14
Interest and investment income
-
-
-
100.00 мян
Interest expense
-
-
-
-
Net interest expenses
-
-
-
100.00 мян
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-13.82 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс